T o the editor: We present a case of cerebral venous thrombosis in an adult patient with nephrotic syndrome.
A 42-year-old male was admitted to Peking University First Hospital complaining of a headache for 3 days followed by clumsiness of both hands and generalized seizures. A diagnosis of nephrotic syndrome (NS) was made 1 month ago, of which the pathology was minimal change disease (Figure 1 and 2) . He was in remission and took prednisone 50 mg/d regularly. Upon physical examination, edema of bilateral lower limbs was noted, and he was comatose without other significant neurological signs. Urine protein excretion was 24.97 g/24 hours and serum albumin 26.7 g/L. Computed tomography venography of the head showed a suspicious filling defect in the superior sagittal sinus as well as subarachnoid hemorrhage.
Subsequent magnetic resonance venography and angiography ( Figure 3 ) further confirmed the diagnosis of superior sagittal sinus thrombosis.
Initial anticoagulation with subcutaneous nadroparin 0.4 ml/12 hours was started within 24 hours, together with plasma transfusion 200 ml/d for 3 days. A measured amount (40 mg and 80 mg, respectively) of intravenous methylprednisolone was given for the first 2 days. Intravenous albumin, glycerol, fructose, and so on were also administered, and levetiracetam was given to treat epilepsy. However, in the first few days, the patient's condition was aggravated. Steroid dosage was changed to 240 mg/d on the third day, continued for 5 days, and then gradually decreased to 40 mg/d. Dosage of albumin was augmented and diuretics added. Gradually, the patient's overall condition improved with amelioration of serum albumin and urine protein. Heparin was continued for 3 weeks and was then switched to warfarin with a target international normalized ratio of 2.0 to 3.0. The method of administration of methylprednisolone was changed from intravenous to oral.
On the 5th day after the patient became conscious, reexamination of magnetic resonance venography showed a mild enlargement of filling defect. However, it also showed the formation of multiple collaterals.
Numerous predisposing conditions of cerebral venous thrombosis (CVT) have been found. However, reports of NS as the underlying reason are rare. More interestingly, although membranous nephropathy is believed to have the strongest association with thrombosis in general, 1 most of the reported cases of CVT with NS are minimal change disease, even in adults where the prevalence of minimal change disease is supposed to be low. 2 On the other hand, cerebral venous system is also an uncommon site for thrombosis in NS. In case-control studies, differences have been found in various thrombophilic factors between CVT and other thrombosis. 3 Therefore, it is possible that different renal pathologies may cause changes in different predisposing factors and thus lead to thrombosis in different locations. As a result, further research on nephrotic pathology may be necessary in such CVT patients in order to obtain a deeper understanding of not only the pathogenesis of CVT but also that of NS.
Anticoagulation has been widely used to treat CVT. 4 No evidence has been found to support differences in outcome between unfractionated heparin and low-molecular-weight heparin. 4 However, given that thrombosis in other locations occurs much more frequently in NS, and that low-molecular-weight heparin is preferred in deep vein thrombosis and pulmonary embolism, we recommend low-molecularweight heparin in this situation. Statistics on dosage is lacking, and we tended to be conservative in this case due to the concurrence of subarachnoid hemorrhage.
However, reexamination of magnetic resonance venography showed growth of thrombus without hemorrhage. This may be partially due to the coexistence of NS, and so a more aggressive anticoagulation therapy may be indicated in such condition. Recanalization rates may be higher for patients who receive thrombolysis, but no randomized controlled trials have been designed to compare thrombolysis with anticoagulation. 4 Generally in patients with CVT or thromboembolism caused by NS, thrombolysis is reserved for those with severe condition. 1, 4 Accordingly, we think the indication of thrombolysis may be similar in a combined situation.
Direct antithrombin replacement or use of fresh frozen plasma could also be necessary, as antithrombin which plays an important role in heparin therapy is often reduced in NS. The duration of vitamin K antagonists as a follow-up therapy remains unclear. The recommended courses of treatment are different for CVT and venous thromboembolism caused by NS, respectively. In addition, if the patient has severe thrombophilia such as natural anticoagulant deficiency, anticoagulants may be given throughout the lifetime. 4 However, NS itself can result in the loss of anticoagulants, 1 leading to confusion as to the cause of anticoagulant deficiency.
Based on the two points mentioned above, accurate course of anticoagulation remains uncertain in CVT patients with NS, but we think that careful weighing of thrombosis and hemorrhage and monitoring of international normalized ratio are necessary.
